Heart attack drug trial halted early: Colchicine's nerve protection unproven
NCT ID NCT04420624
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether the anti-inflammatory drug colchicine could prevent nerve damage in the heart after a heart attack. About 54 adults who had a first heart attack and underwent artery-opening treatment were given colchicine or a placebo for one month. The trial was terminated early, so it is unclear if colchicine provides any benefit for this purpose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- colchicine
- What this could lead to
- If it had worked, this could point toward a way to reduce heart nerve damage after a heart attack.
- What could go wrong
- The study was terminated early with only 54 participants, so we don't have enough data to know if colchicine helps. It was also a small, early-phase trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOCARDIAL INFARCTION, ACUTE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UH Montpellier
Montpellier, 34090, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Timing of additional artery opening after heart attack could save lives
- Massive heart attack data collection launches in tomsk
- Heart attack study halted: could conditioning the heart and arm help?
- Could your gums predict a heart attack?
- Heart attack care: should doctors fix all blockages at once or wait?
- New drug aims to heal hearts after attack – trial results awaited